Skip to content
DataLookout
Menu

NCT06927232

AZA+Lus VS AZA Monotherapy in HR-MDS

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Completed without a posted recruiting period
    • Study completion date changed from estimate of Jan 31, 2027 to Jan 31, 2026
    • Start date changed from estimate of Apr 2025 to Apr 24, 2025
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

overall response rate
Timeframe: 3 months, 6 months

Secondary (6)

complete response rate
rate of transfusion independence
adverse event rate
relapse rate
progress-free survival
Show 1 moreShow less
overall survival

Arms and interventions

Azacitidine+LuspaterceptExperimental
AzacitidineActive comparator

Drugs: Azacitidine (AZA), Luspatercept

Sites

1 site in 1 country

  • Peking union medical college hospitalBeijing, N/A 不适用, China